Erasca Inc (ERAS) Stock Forecast & Price Target

Erasca is viewed favorably because its pipeline is advancing with multiple near- and mid-term catalysts, led by incrementally positive Phase 1 AURORAS-1 data for ERAS-0015 and management’s plan to prioritize NSCLC and 1L PDAC for potential pivotal study initiations starting in 2027. The company also broadened its strategic optionality through a Phase 1 collaboration with MRK on ERAS-0015 plus pembrolizumab in RASm solid tumors, while first clinical data for ERAS-4001 is expected in 2H26. Financially, a $500M equity raise and $409M in cash and equivalents at the end of 2Q provide a strengthened balance sheet to fund development across its RAS/MAPK-focused precision oncology pipeline.

Erasca is viewed negatively because its thesis depends on highly uncertain R&D, regulatory, and commercial execution in a clinically unproven precision oncology pipeline focused on RAS/MAPK-driven cancers. The company’s two clinical-stage assets, ERAS-0015 and ERAS-4001, still face meaningful development risk, while ERAS-12 remains only at the discovery stage, leaving limited near-term validation and substantial scientific uncertainty. On top of that, the company faces the risk of new competitors, lower-than-expected product sales, intellectual property challenges, management execution issues, and potential M&A missteps, all of which could materially weaken future value creation.